Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. (2022)
Attributed to:
Driving innovation in precision medicine through translational life sciences research at the University of Leicester
funded by
UKRI
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/cancers14143452
PubMed Identifier: 35884511
Publication URI: http://europepmc.org/abstract/MED/35884511
Type: Journal Article/Review
Volume: 14
Parent Publication: Cancers
Issue: 14
ISSN: 2072-6694